A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal

Rheumatology

Volumn 44, Issue 11, 2005, Pages 1414-1421

  Choy, Ernest H S ^b   Smith, C ^b   Dore C J ^a   Scott, D L ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti rheumatic drugs; Combination therapy; DMARD; Meta analysis; Randomized controlled trial; Rheumatoid arthritis; Treatment

Indexed keywords

ANTIMALARIAL AGENT; AURANOFIN; AZATHIOPRINE; BUCLIZINE; CHLOROQUINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; EMBASE; HUMAN; INTERMETHOD COMPARISON; MEDLINE; META ANALYSIS; MONOTHERAPY; PARALLEL DESIGN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VALIDATION PROCESS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 27744566645     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei031     Document Type: Article

References (74)

1. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence? Rheumatology 2001;40:1211-20.
2. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002;359:1173-7.
3. Simon LS. DMARDs in the treatment of rheumatoid arthritis: Current agents and future developments. Int J Clin Pract 2000;54:243-9.
4. Bingham S, Emery P. Combination therapy in rheumatoid arthritis. Springer Semin Immunopathol 2001;23:165-83.
5. Garrood T, Scott DL. Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Biodrugs 2001;15: 543-61.
6. Goekoop YP, Allaart CF, Breedveld FC, Dijkmans BA. Combination therapy in rheumatoid arthritis. Curr Opin Rheumatol 2001;13: 177-83.
7. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.
8. O'Dell JR. Combinations of conventional disease-modifying anti-rheumatic drugs. Rheum Dis Clin North Am 2001;27:415-26.
9. Breedveld FC. Current and future management approaches for rheumatoid arthritis. Arthritis Res 2002;4(Suppl 2): S16-S21.
10. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
11. Begg C, Cho M, Eastwood S et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. J Am Med Assoc 1996;276:637-9.
12. Jadad AR, Moore A, Carroll D et al. Assessing the quality of reports of randomized controlled trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
13. Moreland LW, Pratt PW, Mayes MD et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995;38:1581-8.
14. Lacki JK, Leszczynski P, Mackiewicz SH. Intravenous cyclophosphamide combined with methylprednisolone in the treatment of severe refractory rheumatoid arthritis: The effect on lymphocytes. J Invest Aller Clin Immunol 1996;6:232-6.
15. Moreland LW, Morgan EE, Adamson TC 3rd et al. T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum 1998;41:1919-29.
16. Haagsma CJ, Blom HJ, van Riel PL et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.
17. Clegg DO, Dietz F, Duffy J et al. Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 1997;24:1896-902.
18. Haagsma CJ, Russel FG, Vree TB, Van Riel PL, Van de Putte LB. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: Pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol 1996;42:195-200.
19. Lopez-Mendez A, Daniel WW, Reading JC, Ward JR, Alarcon GS. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 1993;36:1364-9.
20. Heytman M, Ahern MJ, Smith MD, Roberts-Thomson PJ. The longterm effect of pulsed corticosteroids on the efficacy and toxicity of chrysotherapy in rheumatoid arthritis. J Rheumatol 1994;21:435-41.
21. Willkens RF, Stablein D. Combination treatment of rheumatoid arthritis using azathioprine and methotrexate: A 48 week controlled clinical trial. J Rheumatol Suppl 1996;44:64-8.
22. Haagsma CJ, van Riel PL, van de Putte LB. Combining sulphasalazine and methotrexate in rheumatoid arthritis: Early clinical impressions. Br J Rheumatol 1995;34(Suppl. 2):104-8.
23. Krause D. Long-term combination therapy of chronic polyarthritis: methotrexate and parenteral gold. Z Rheumatol 1998;57:37-40.
24. Tsitlanadze VG, Shalamberidze LP, Dzidziguri LM et al. The comparative effectiveness of using basic preparations in the combined therapy of rheumatoid arthritis [in Russian]. Terapevt Arkh 1991; 63:101-5.
25. Proudman SM, Conaghan PG, Richardson C et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000;43:1809-19.
26. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
27. Haagsma CJ, van Riel PL, de Rooij DJ et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: A randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol 1994;33:1049-55.
28. Bunch TW, O'Duffy JD, Tompkins RB, O'Fallon WM. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum 1984;27:267-76.
29. Hansen TM, Kryger P, Elling H et al. Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. Br Med J 1990;301:268-70.
30. van den Borne BE, Landewe RB, Goei The HS et al. Combination therapy in recent onset rheumatoid arthritis: A randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998;25:1493-8.
31. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995;333:137-41.
32. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis-no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol 1993;20:645-9.
33. Yasuda M, Sakai K, Oribe M et al. Efficacy of additive DMARD therapy in patients with rheumatoid arthritis. Double blind controlled trial using bucillamine and placebo with maintenance doses of gold sodium thiomalate. J Rheumatol 1994;21:44-50.
34. Bendix G, Bjelle A. Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: A double-blind placebo-controlled study. Br J Rheumatol 1996;35:1142-9.
35. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
36. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
37. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
38. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841-50.
39. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142-6.
40. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36:1082-8.
41. Dougados M, Combe B, Cantagrel A et al. Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58:220-5.
42. O'Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
43. Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum 1995;38:1799-806.
44. Faarvang KL, Egsmose C, Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: A randomised double blind trial. Ann Rheum Dis 1993;52:711-15.
45. Ferraz MB, Pinheiro GR, Helfenstein M et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial. Scand J Rheumatol 1994;23:231-6.
46. Scott DL, Dawes PT, Tunn E et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: A prospective, randomized, placebo-controlled study. Br J Rheumatol 1989;28: 128-33.
47. Gibson TG, Emery P, Armstrong RD, Crisp AJ, Panayi GS. Combined D-penicillamine and chloroquine treatment - a comparative study. Br J Rheumatol 1987;26:279-84.
48. Calguneri M, Pay S, Caliskaner Z et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17:699-704.
49. Williams HJ, Ward JR, Reading JC et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992; 35:259-69.
50. Trnavsky K, Gatterova J, Linduskova M, Peliskova Z. Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis. Z Rheumatol 1993;52:292-6.
51. Gough A, Sheeran T, Arthur V, Panayi G, Emery P. Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis. A pilot study. Scand J Rheumatol 1994;23:46-8.
52. Ciconelli RM, Ferraz MB, Visioni RA, Oliveira LM, Atra E. A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis. Br J Rheumatol 1996;35:150-4.
53. Corkill MM, Kirkham BW, Chikanza IC, Gibson TG, Panayi GS. Intramuscular depot methylprenisolone induction of chrysotherapy in rheumatoid arthritis: A 24-week randomised controlled trial. Br J Rheumatol 1990;29:274-9.
54. van Gestel AM, Laan RF, Haagsma CJ, van de Putte LB, van Riel PL. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol 1995;34:347-51.
55. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
56. van Der Veen MJ, Bijlsma JW. The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. Clin Rheumatol 1993;12:500-5.
57. Wong CS, Champion G, Smith MD et al. Does steroid pulsing influence the efficacy and toxicity of chrysotherapy? A double blind, placebo controlled study. Ann Rheum Dis 1990;49:370-2.
58. Gerards AH, Landewe RB, Prins AP et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: A double blind randomised placebo controlled trial. Ann Rheum Dis 2003;62:291-6.
59. Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
60. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
61. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
62. Klareskog L, van der Heijde D, de Jager JP et al. [TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators]. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004;363:675-81.
63. Cohen SB, Moreland LW, Cush JJ et al. A multicenter double-blind randomized placebo-controlled trial of Kineret® (anakinra), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate therapy. Ann Rheum Dis 2004.
64. Miranda JM, Alvarez-Nemegyei J, Saavedra MA et al. (GRECIA Group). A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis. Arch Med Res 2004;35:36-42.
65. Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S. Radiographic progression in early rheumatoid arthritis: A 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 2003;42:1545-9.
66. Saag KG. Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthritis Rheum 2001;45:468-71.
67. Hawley DJ, Wolfe F, Pincus T. Use of combination therapy in the routine care of patients with rheumatoid arthritis: Physician and patient surveys. Clin Exp Rheumatol 1999;17(Suppl. 18):S78-S82.
68. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: Methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;29:2521-4.
69. Boers M, Ramsden M. Long acting drug combinations in rheumatoid arthritis: A formal overview. J Rheumatol 1991;18:316-24.
70. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 1994;37:1487-91.
71. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: Updated systematic review. Br J Rheumatol 1998;37:612-9.
72. van Beusekom I, MacLean C, Allaart CF, Breedveld FC. Systematic review of combination DMARD therapy in rheumatoid arthritis. Rand Europe 2000 (RE-2000-14).
73. Hochberg MC, Tracy JK, Flores RH. 'Stepping-up' from methotrexate: A systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis 2001; 60(Suppl. 3):51-4.
74. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002;61(Suppl. 2):2-7.